Developed skills and lines of research
Marco Rusnati graduated in Biology from the University of Milan in 1985 and was a University Researcher in Pathology and Immunology at the University of Brescia. In 2002, he became an Associate Professor at the section of Experimental Oncology and Immunology at the University of Brescia. He is currently a Full Professor at the Department of Molecular and Translational Medicine at the University of Brescia. Furthermore, in 2012 he created the macromolecular interactions analysis unit at the University of Brescia, of which he is still the director. He is co-author of over 160 publications in international journals.
Projects funded by FFC Ricerca as Principal Investigator or as Research Manager
FFC#10/2019
Rescuing defective CFTR-F508del applying a drug repositioning strategy based on computational studies, surface plasmon resonance and cell-based assays
FFC#11/2018
Rescuing defective CFTR applying a drug repositioning strategy based on computational studies, surface plasmon resonance and cell-based assays
FFC#6/2014
Development of novel methodologies for the identification of CFTR-targeted drugs: a multidisciplinary approach using Real Time Surface Plasmon Resonance interaction assay supported by bioinformatics strategies on HPC infrastructures
Publications from FFC Research projects
Rusnati M, Sala D, Orro A, et al., Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance. Molecules. 2018 Jan 8;23(1). pii: E120. doi: 10.3390/molecules23010120.
Bianconi I, Alcalá-Franco B, et al. Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa. Front Immunol. 2019 Jan 9;9:3021. doi: 10.3389/fimmu.2018.03021. eCollection 2018.
Fossa P. Studi strutturistici sulla proteina CFTR: opportunità e prospettive. La chimica e l’industria, 2019
Pasqualina D’Ursi, Matteo Uggeri, Chiara Urbinati, et al. Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue. Sensors and Actuators B: Chemical, 2019. DOI: 10.1016/j.snb.2019.127131